Cochrane · systematic review · CD011169
Selective oestrogen receptor modulators (SERMs) for endometriosis
van Hoesel, MH, Chen, YL, Zheng, A, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
Gynaecology and FertilityAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
6
No studies
1
Included studies
NR
No studies 1 · 14.3%Ungraded 0 · 0%Very low 6 · 85.7%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Raloxifene versus placebo for endometriosis
Population: women with endometriosis, following complete surgical excision of lesions
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Relief of pelvic pain Raloxifene vs placebo | no estimate extracted | NR | No studies |
Adverse events ‐ pelvic pain Raloxifene vs placebo | RR 1.25 [0.63, 2.45] | 1 study · 93 participants | Very low Downgraded: risk of bias |
Adverse events ‐ ovarian cyst Raloxifene vs placebo | RR 1.57 [0.55, 4.43] | 1 study · 93 participants | Very low Downgraded: risk of bias |
Adverse events ‐ headache Raloxifene vs placebo | RR 1.06 [0.48, 2.37] | 1 study · 93 participants | Very low Downgraded: risk of bias |
Adverse events ‐ migraine Raloxifene vs placebo | RR 0.73 [0.28, 1.95] | 1 study · 93 participants | Very low Downgraded: risk of bias |
Adverse events ‐ depression Raloxifene vs placebo | RR 1.91 [0.62, 5.92] | 1 study · 93 participants | Very low Downgraded: risk of bias |
Biopsy‐proven recurrence of endometriosis Raloxifene vs placebo | RR 1.2 [0.66, 6.21] | 1 study · 93 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |